Anbogen Therapeutics, Inc.
2 clinical trials · Sponsor
◉ Watch Anbogen Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC (NCT07244705) | Anbogen Therapeutics, Inc. | 2025-11-01 |
| Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients (NCT05532696) | Anbogen Therapeutics, Inc. | 2022-09-27 |
Track Anbogen Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.